Who is sponsoring NCT02197806?

NCT02197806 is sponsored by Allergan.

What condition does NCT02197806 study?

NCT02197806 studies Presbyopia.

What drugs are being tested in NCT02197806?

Interventions: AGN-199201, AGN-190584, AGN-199201 Vehicle.

What is the status of NCT02197806?

NCT02197806 is currently COMPLETED.

Last reviewed 2015-10-30 · How we verify

Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia

NCT02197806 Phase 2 COMPLETED Results posted

A study to evaluate the safety and efficacy of AGN-199201 alone, AGN-190584 alone and concurrent use of AGN-199201 and AGN-190584 in patients with presbyopia (inability to focus for near vision).

Details

Lead sponsor	Allergan
Phase	Phase 2
Status	COMPLETED
Enrolment	65
Start date	2014-07
Completion	2014-11

Conditions

Presbyopia

Interventions

AGN-199201
AGN-190584
AGN-199201 Vehicle

Primary outcomes

Percentage of Participants With at Least a 2 Line Improvement From Baseline in Uncorrected Near Visual Acuity (UNVA) in the Non-Dominant Eye — Baseline, Day 3
UNVA is assessed without corrective lenses in the non-dominant eye. UNVA is measured using an eye chart and is reported as the number of lines read correctly. The lower the number of lines read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of lines read correctly means that vision has improved. The percentages of patients with at least a 2 or more line improvement in UNVA in the non-dominant eye are presented.

Countries

United States